Anatomical and Functional Outcomes of Macular Edema Complicating Retinal Vein Occlusions (RVO) Treated with Intravitreal Anti-VEGF Injections at Bouaké University Hospital

Objective: To describe the anatomical and functional outcomes of macular edema complicating Retinal Vein Occlusion (RVO) in patients treated with intravitreal anti-VEGF injections, with the aim of improving its management. Patients and methods: This was a prospective descriptive study conducted in the Department of Ophthalmology of Bouaké University Hospital from 18/08/2023 to 18/08/2025, over a period of 24 months. All patients with an accessible fundus examination, in whom RVO complicated by macular edema was confirmed by OCT and who received three intravitreal anti-VEGF injections (aflibercept), were included. Patients in whom macular edema could not be confirmed by OCT and those who did not receive the three intravitreal anti-VEGF injections were excluded. The parameters studied were epidemiological (age, sex, occupation, risk factors), clinical (distance visual acuity, intraocular pressure, RVO location, fundus lesions before and after anti-VEGF injections) and para -clinical (central foveal thickness before and after anti-VEGF injections). Data entry and analysis were performed using Epi Info version 7.1.3. Word-processing and tables were produced using Microsoft Word. Results: The hospital frequency of macular edema complicating RVO was 30% (n=24). The mean age was 58.41 years, ranging from 31 to 77 years. There was a male predominance of 75% (n=18), with a sex ratio of 3. The most common risk factor was glaucoma, in 50% (n=12) of cases. The right eye was most affected, accounting for 58.33% of cases (n=14). Initial distance visual acuity was ≤1/20 in 83.33% (n=20) of cases. Mean intraocular pressure was 23.33 mmHg, ranging from 18 to 35 mmHg. Central Retinal Vein Occlusion (CRVO) predominated in 50% of cases (n=12), followed by inferior Branch Retinal Vein Occlusion (BRVO) in 41.66% (n=10). Mean central macular thickness was 524.58 µm, ranging from 292 to 1075 µm. After three anti-VEGF injections, clinical signs of RVO and macular edema regressed in 100% of cases (n=24). Distance visual acuity improved to between 1/10 and 3/10 in 91.66% (n=22) of patients and central macular thickness decreased by 291.33 µm, with a mean post-treatment central macular thickness of 233.25 µm. Conclusion: Intravitreal aflibercept injections in the management of macular edema complicating retinal vein occlusions improve the anatomical and functional prognosis of the affected eye.

Authors

Institutions

Publication Details

Journal
Journal of Ophthalmology and Advance Research
Published
2026-11-15
DOI
https://doi.org/10.46889/joar.2026.7309
Primary Topic
Retinal Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Anatomical and Functional Outcomes of Macular Edema Complicating Retinal Vein Occlusions (RVO) Treated with Intravitreal Anti-VEGF Injections at Bouaké University Hospital

Gosse François Diomandé, Godé LE, Yves Ouattara, Goulé AM et al.
Journal of Ophthalmology and Advance Research
Retinal Diseases and Treatments
article

Anatomical and Functional Outcomes of Macular Edema Complicating Retinal Vein Occlusions (RVO) Treated with Intravitreal Anti-VEGF Injections at Bouaké University Hospital

Gosse François Diomandé, Godé LE, Yves Ouattara, Goulé AM, I.A. Diomandé, Koffi KAP, Koffi KF-H, Bilé PEFK, Babayeju RLO, Diabaté Z, Konan MP, Ikpo G
article en

Abstract

Objective: To describe the anatomical and functional outcomes of macular edema complicating Retinal Vein Occlusion (RVO) in patients treated with intravitreal anti-VEGF injections, with the aim of improving its management. Patients and methods: This was a prospective descriptive study conducted in the Department of Ophthalmology of Bouaké University Hospital from 18/08/2023 to 18/08/2025, over a period of 24 months. All patients with an accessible fundus examination, in whom RVO complicated by macular edema was confirmed by OCT and who received three intravitreal anti-VEGF injections (aflibercept), were included. Patients in whom macular edema could not be confirmed by OCT and those who did not receive the three intravitreal anti-VEGF injections were excluded. The parameters studied were epidemiological (age, sex, occupation, risk factors), clinical (distance visual acuity, intraocular pressure, RVO location, fundus lesions before and after anti-VEGF injections) and para -clinical (central foveal thickness before and after anti-VEGF injections). Data entry and analysis were performed using Epi Info version 7.1.3. Word-processing and tables were produced using Microsoft Word. Results: The hospital frequency of macular edema complicating RVO was 30% (n=24). The mean age was 58.41 years, ranging from 31 to 77 years. There was a male predominance of 75% (n=18), with a sex ratio of 3. The most common risk factor was glaucoma, in 50% (n=12) of cases. The right eye was most affected, accounting for 58.33% of cases (n=14). Initial distance visual acuity was ≤1/20 in 83.33% (n=20) of cases. Mean intraocular pressure was 23.33 mmHg, ranging from 18 to 35 mmHg. Central Retinal Vein Occlusion (CRVO) predominated in 50% of cases (n=12), followed by inferior Branch Retinal Vein Occlusion (BRVO) in 41.66% (n=10). Mean central macular thickness was 524.58 µm, ranging from 292 to 1075 µm. After three anti-VEGF injections, clinical signs of RVO and macular edema regressed in 100% of cases (n=24). Distance visual acuity improved to between 1/10 and 3/10 in 91.66% (n=22) of patients and central macular thickness decreased by 291.33 µm, with a mean post-treatment central macular thickness of 233.25 µm. Conclusion: Intravitreal aflibercept injections in the management of macular edema complicating retinal vein occlusions improve the anatomical and functional prognosis of the affected eye.

Journal of Ophthalmology and Advance ResearchVol. 7(3)
Université Alassane Ouattara (CI), University Hospital Medical Center at Treichville (CI), Centre Hospitalier Universitaire de Cocody (CI)
Retinal Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon